NCT03249740 - A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 29, 2017

Primary Completion Date

September 13, 2018

Study Completion Date

January 16, 2019

Conditions

Neovascular Age-Related Macular Degeneration

Interventions

DRUG

GB-102

Intravitreal injection of GB-102

DRUG

Aflibercept

Intravitreal injection of Aflibercept.

Trial Locations (8)

Ophthalmic Consultants of Long Island, Lynbrook

Midwest Eye Institute, Indianapolis

Texas Retina Associates, Arlington

Medical Center Ophthalmology Associates, San Antonio

Retina Research Center, PLLC, Austin

Retina Research Institute of Texas, Abilene

Retinal Consultants of Arizona, Gilbert

Retina-Vitreous Associates Medical Group, Beverly Hills